FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program

医学 授权 事先授权 医学物理学 重症监护医学 医疗急救 药理学 计算机安全 计算机科学
作者
Kushal T. Kadakia,Sanket S. Dhruva,Joseph S. Ross,James Burke,James L. Johnston,Reshma Ramachandran,Harlan M. Krumholz,Vinay K. Rathi
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:185 (8): 996-996 被引量:2
标识
DOI:10.1001/jamainternmed.2025.2235
摘要

Importance Congress established the US Food and Drug Administration (FDA) Breakthrough Devices Program (BDP) in 2016 to promote technological innovation and facilitate patient access. However, the clinical and regulatory characteristics of FDA-designated breakthrough devices have not been assessed. Objective To characterize technological novelty, FDA review times, and premarket and postmarket evidence requirements for therapeutic breakthrough-designated devices. Design and Setting This cross-sectional study analyzed publicly available FDA data for all therapeutic breakthrough-designated devices receiving FDA authorization between January 1, 2016, and September 30, 2024. Main Outcomes and Measures (1) Device novelty (first of a kind and first commercialized launch); (2) FDA premarket review times (compared with Medical Device User Fee Authorization [MDUFA] goals); (3) premarket pivotal study characteristics; and (4) postmarket regulatory experience (FDA-required studies and recalls). Results Between January 1, 2016, and September 30, 2024, the FDA granted breakthrough designations to 1041 devices, 127 of which have been authorized (12.2%), including 75 therapeutic devices (59.1%). Thirty-four of 75 therapeutic devices (45.3%) were classified as high-risk; within this subgroup, 23 were first of a kind (67.6%) and 14 were first commercialized in the US (41.4%). The mean (SD) FDA review time was 225.8 (107.6) days for all 75 devices and 243.3 (98.4) days for the 34 high-risk devices. MDUFA goals for FDA review times applied to 30 high-risk devices, of which 22 (73.3%) were reviewed before statutory target timeframes. Most therapeutic devices (89.3% [67 of 75]) underwent premarket clinical testing, totaling 75 pivotal studies evaluating 81 primary effectiveness end points. Forty end points (49.4%) incorporated surrogate measures of effectiveness, and 15 (18.5%) lacked statistical testing. End points had short follow-up durations (median, 6 months [IQR, 3.8-12 months] for implantable devices). The FDA required 46 postmarket studies for 30 breakthrough-designated devices (40.0%); 19 studies reported delays (41.3%). The mean (SD) US market life to date was 2.4 (1.9) years, during which 12.0% of devices (9 of 75) were recalled, including 1 class I (1.3%) (ie, highest severity) recall. Conclusions and Relevance This study found that most therapeutic breakthrough–designated devices are novel and reviewed by the FDA before statutory target timeframes. However, uncertainty about benefits and risks for some devices raises questions whether BDP is consistently fulfilling program objectives to improve public health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZJY完成签到,获得积分10
刚刚
勤恳浩然发布了新的文献求助10
刚刚
再睡亿分钟完成签到,获得积分10
刚刚
衣锦夜行发布了新的文献求助10
1秒前
SCI的豆发布了新的文献求助10
1秒前
1秒前
2秒前
小安的应助被yu采纳,获得10
3秒前
1122发布了新的文献求助10
3秒前
3秒前
上官若男的应助被一只小绵羊采纳,获得50
3秒前
zhangyupei发布了新的文献求助10
3秒前
香蕉觅云的应助被受伤白安采纳,获得10
3秒前
4秒前
4秒前
jane完成签到 ,获得积分10
5秒前
rinne发布了新的文献求助10
5秒前
fantasy的应助被we采纳,获得10
5秒前
bluemoon发布了新的文献求助10
6秒前
情怀的应助被常温可乐采纳,获得10
6秒前
7秒前
Ava的应助被干净的鸣凤采纳,获得20
7秒前
7秒前
Lucas的应助被风中的宛白采纳,获得10
7秒前
8秒前
大模型的应助被风中的宛白采纳,获得10
8秒前
bkagyin的应助被风中的宛白采纳,获得10
8秒前
8秒前
爆米花的应助被风中的宛白采纳,获得10
8秒前
yy发布了新的文献求助10
8秒前
科研通AI6.3的应助被1122采纳,获得10
9秒前
粒粒发布了新的文献求助10
10秒前
共享精神的应助被yy采纳,获得10
10秒前
传奇3的应助被柴六斤采纳,获得10
12秒前
晚霞跌落星河的应助被MADAO采纳,获得30
12秒前
12秒前
翟思宇发布了新的文献求助10
13秒前
didida发布了新的文献求助10
13秒前
cc完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651